Kieran C Breen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9083883/publications.pdf

Version: 2024-02-01

79 3,668 29 59 g-index

79 79 79 79 4091

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Physical activity for adolescents with severe mental illness: a systematic scoping review. International Review of Sport and Exercise Psychology, 2023, 16, 176-209.	5.7	4
2	A new era in psychiatry: the impacts of COVID-19 and the shift to telepsychiatry on clinical practice and clinician well-being. Journal of Enabling Technologies, 2022, ahead-of-print, .	1.2	1
3	The impact of inequality on mental illness: thematic analysis on clinical notes. Journal of Forensic Practice, 2021, ahead-of-print, .	0.5	1
4	Inequalities in women's medium or low secure mental health settings: a scoping review. Journal of Forensic Practice, 2021, 23, 254-271.	0.5	1
5	Adolescent inpatient completers of dialectical behaviour therapy. Journal of Forensic Practice, 2019, 22, 29-39.	0.5	2
6	Precompetitive Data Sharing as a Catalyst toÂAddress Unmet Needs in Parkinson's Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	2.8	25
7	What impacts on the stress symptoms of Parkinson's carers? Results from the Parkinson's UK Members' Survey. Disability and Rehabilitation, 2014, 36, 199-204.	1.8	23
8	Non-motor symptoms of Parkinson's disease: the patient's perspective. Journal of Neural Transmission, 2013, 120, 531-535.	2.8	59
9	Parkinson's UK: Pushing the Search for a Cure to New Levels. Stem Cells Translational Medicine, 2012, 1, 81-82.	3.3	0
10	Nicotine modifies in vivo and in vitro rat hippocampal amyloid precursor protein processing in young but not old rats. Neuroscience Letters, 2012, 514, 22-26.	2.1	5
11	Parkinson's U.K.: Pushing the search for a cure to new levels. Stem Cells, 2012, 30, 587-588.	3.2	0
12	Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. The Cochrane Library, 2011, , CD008535.	2.8	11
13	Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. The Cochrane Library, 2011, , CD008454.	2.8	81
14	Helicobacter pylori eradication for Parkinson's disease. The Cochrane Library, 2011, , CD008453.	2.8	35
15	Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Movement Disorders, 2009, 24, 2379-2385.	3.9	47
16	The amyloidogenic potential and behavioral correlates of stress. Molecular Psychiatry, 2009, 14, 95-105.	7.9	154
17	Glucocorticoids trigger Alzheimer diseaseâ€ike pathobiochemistry in rat neuronal cells expressing human tau. Journal of Neurochemistry, 2008, 107, 385-397.	3.9	82
18	The effect of stress on the expression of the amyloid precursor protein in rat brain. Neuroscience Letters, 2008, 431, 197-200.	2.1	17

#	Article	IF	CITATIONS
19	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders, 2007, 22, 1623-1629.	3.9	461
20	The metric properties of a novel nonâ€motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 2007, 22, 1901-1911.	3.9	838
21	Autoinsertion of soluble oligomers of Alzheimer's Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface. BMC Structural Biology, 2006, 6, 21.	2.3	40
22	The effects of chronic nicotine on spatial learning and bromodeoxyuridine incorporation into the dentate gyrus of the rat. Psychopharmacology, 2006, 184, 540-546.	3.1	51
23	A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 465-469.	1.9	130
24	Axonal transport of the cellular prion protein is increased during axon regeneration. Journal of Neurochemistry, 2005, 92, 1044-1053.	3.9	18
25	Lipopolysaccharide stimulates the secretion of the amyloid precursor protein via a protein kinase C-mediated pathway. Neurobiology of Disease, 2005, 19, 400-406.	4.4	10
26	The potential role of tau protein O-glycosylation in Alzheimer's disease. Journal of Alzheimer's Disease, 2004, 6, 489-495.	2.6	85
27	Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors. Clinical Biochemistry, 2004, 37, 98-104.	1.9	76
28	Inducible form of nitric oxide synthase expression in rat cortical neuronal cells in vitro. Neurobiology of Disease, 2004, 17, 70-76.	4.4	17
29	The dynamic localization of the glucocorticoid receptor in rat C6 glioma cell mitochondria. Molecular and Cellular Endocrinology, 2003, 209, 51-60.	3.2	48
30	The role of protein phosphorylation in $\hat{l}\pm 2,6(N)$ -sialyltransferase activity. Biochemical and Biophysical Research Communications, 2003, 309, 32-35.	2.1	7
31	The over-expression of the wild type or mutant forms of the presenilin-1 protein alters glycoprotein processing in a human neuroblastoma cell line. Neuroscience Letters, 2003, 346, 53-56.	2.1	16
32	The role of protein glycosylation in the control of cellularN-sialyltransferase activity. FEBS Letters, 2002, 517, 215-218.	2.8	15
33	The role of post-translational modification in ϕamyloid precursor protein processing. Biochemical Society Symposia, 2001, 67, 23-36.	2.7	33
34	Serum Expression of Sialyltransferase in Normal and Down's Syndrome-Affected Pregnancy. Annals of Clinical Biochemistry, 2000, 37, 507-511.	1.6	0
35	Inhibition of N-glycan processing alters axonal transport of synaptic glycoproteins in vivo. NeuroReport, 2000, 11, 1543-1547.	1.2	37
36	Activation of phospholipase D by metabotropic glutamate receptor agonists in rat cerebrocortical synaptosomes. British Journal of Pharmacology, 2000, 131, 1011-1018.	5.4	19

3

#	Article	IF	Citations
37	Factors influencing the processing and function of the amyloid \hat{l}^2 precursor proteinâ \in "a potential therapeutic target in Alzheimer's disease?. , 2000, 86, 111-144.		39
38	Retinoic acid induction of sialyltransferase activity in neuroblastoma cells of differing sialylation potentials., 2000, 17, 781-786.		0
39	Protein Kinase C Activation Potentiates the Rapid Secretion of the Amyloid Precursor Protein from Rat Cortical Synaptosomes. Journal of Neurochemistry, 1999, 72, 273-281.	3.9	17
40	Overexpression of alpha2,3 sialyltransferase in neuroblastoma cells results in an upset in the glycosylation process., 1999, 16, 649-657.		6
41	Overexpression of the $\hat{l}\pm 2,6$ (N) sialyltransferase enzyme in human and rat neural cell lines is associated with increased expression of the polysialic acid epitope., 1999, 58, 641-651.		14
42	The effect of corticosteroids on amyloid \hat{l}^2 precursor protein/amyloid precursor-like protein expression and processing in vivo. Neuroscience Letters, 1999, 276, 61-64.	2.1	33
43	The role of the protein glycosylation state in the control of cellular transport of the amyloid \hat{l}^2 precursor protein. Neuroscience, 1999, 90, 15-25.	2.3	52
44	Modest cholinergic deafferentation fails to alter hippocampal G-proteins. Neurochemistry International, 1999, 35, 59-64.	3.8	1
45	Protein Kinase C Activation Potentiates the Rapid Secretion of the Amyloid Precursor Protein from Rat Cortical Synaptosomes. Journal of Neurochemistry, 1999, 72, 273-281.	3.9	17
46	The generation and characterization of a rat neural cell line overexpressing the alpha2,6(N) sialyltransferase. Glycoconjugate Journal, 1998, 15, 199-202.	2.7	13
47	Stimulation of Sialyltransferase by Subchronic Low-Level Lead Exposure in the Developing Nervous System. Toxicology and Applied Pharmacology, 1998, 151, 16-21.	2.8	22
48	Glucocorticoid induction of the ?2,6 sialyltransferase enzyme in a mouse neural cell line. Journal of Neuroscience Research, 1998, 51, 619-626.	2.9	11
49	The effect of corticosteroids on serum sialyltransferase enzyme activities in the rat. Biochimica Et Biophysica Acta - General Subjects, 1998, 1379, 23-28.	2.4	13
50	The role of glycoproteins in neural development, function, and disease. Molecular Neurobiology, 1998, 16, 163-220.	4.0	43
51	The interaction between chronic low-level lead and the amyloid \hat{l}^2 precursor protein. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 90-98.	3.0	8
52	Neural cell adhesion molecule expression in the developing chick otic vesicle. Biochemical Society Transactions, 1997, 25, 10S-10S.	3.4	1
53	The biochemical consequences of $\hat{l}\pm 2,6(N)$ sialyltransferase induction by dexamethasone on sialoglycoprotein expression in the rat H411e hepatoma cell line. FEBS Letters, 1997, 413, 389-393.	2.8	3
54	Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function. Biological Psychiatry, 1997, 41, 1131-1136.	1.3	38

#	Article	IF	Citations
55	Individual isoforms of the amyloid ?precursor protein demonstrate differential adhesive potentials to constituents of the extracellular matrix., 1997, 49, 154-160.		16
56	The expression of neural cell sialoglycoproteins following glucocorticoid regulation of sialyltransferase activity in vivo. Cellular and Molecular Neurobiology, 1996, 16, 433-438.	3.3	6
57	Evidence for a correlation between ambient cholesterol levels and soluble plasma sialyltransferase enzyme activity. Glycoconjugate Journal, 1996, 13, 525-528.	2.7	1
58	Tissue-specific regulation of sialyltransferase activities in the rat by corticosteroids in vivo. Glycobiology, 1996, 6, 15-22.	2. 5	41
59	A Decrease in Neural Sialyltransferase Activity in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1995, 6, 185-190.	1.5	24
60	Heparin induction of the \hat{I}^2 -amyloid precursor protein (A \hat{I}^2 PP) in a neural cell line is regulated by cell confluency state. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 17-21.	3.0	1
61	The control of sialyltransferase activity in tumor-cell lines derived from different tissues is multifactorial. FEBS Letters, 1995, 369, 260-262.	2.8	4
62	A decrease in serum sialyltransferase levels in Alzheimer's disease. Neurobiology of Aging, 1994, 15, 99-102.	3.1	49
63	Glucocorticoid potentiation of lead neurotoxicity in the mouse HN9 hippocampal cell line. Toxicology in Vitro, 1994, 8, 407-411.	2.4	8
64	Increase in extracellular NCAM and amyloid precursor protein following induction of long-term potentiation in the dentate gyrus of anaesthetized rats. Neuroscience Letters, 1994, 169, 77-80.	2.1	124
65	The effect of cell confluency state on the expression of neural cell surface glycoconjugates. NeuroReport, 1994, 5, 970-972.	1.2	16
66	APP-collagen interaction is mediated by a heparin bridge mechanism. Molecular and Chemical Neuropathology, 1992, 16, 109-121.	1.0	50
67	Temporal expression of neurofilament polypeptides in differentiating neuroblastoma cells. NeuroReport, 1991, 2, 21-24.	1.2	13
68	Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. Journal of Neuroscience Research, 1991, 28, 90-100.	2.9	227
69	Intraventricular infusions of antibodies to amyloid- \hat{l}^2 -protein precursor impair the acquisition of a passive avoidance response in the rat. Neuroscience Letters, 1990, 115, 97-102.	2.1	92
70	Cyclic AMP-dependent expression of the heavy neurofilament (NF-H) polypeptide in differentiating neuroblastoma cells. Molecular Brain Research, 1990, 7, 161-165.	2.3	10
71	The developmental regulation of the L2/HNK-1 and L3 carbohydrate epitopes in mouse brain Evidence for separate control of lipid- and protein-bound epitopes. FEBS Letters, 1989, 247, 36-40.	2.8	6
72	Differentiation-Dependent Sialylation of Individual Neural Cell Adhesion Molecule Polypeptides During Postnatal Development. Journal of Neurochemistry, 1988, 50, 712-716.	3.9	31

KIERAN C BREEN

#	Article	IF	CITATIONS
73	Lead stimulates Golgi sialyltransferase at times coincident with the embryonic to adult conversion of the neural cell adhesion molecule (N-CAM). Toxicology, 1988, 49, 71-76.	4.2	24
74	Partial sequence of the rat heavy neurofilament polypeptide (NF-H) Identification of putative phosphorylation sites. FEBS Letters, 1988, 241, 213-218.	2.8	18
75	Soluble rat brain sialidase does not influence intracellular glycosylation of Golgi sialyltransferase or its constitutive glycoproteins. Neuroscience Letters, 1988, 88, 308-312.	2.1	3
76	Perturbations of cellular functions integral to neural tube formation by the putative teratogen sodium valproate. Toxicology in Vitro, 1988, 2, 43-48.	2.4	22
77	Postnatal D2-CAM/N-CAM Sialylation State Is Controlled by a Developmentally Regulated Golgi Sialyltransferase. Journal of Neurochemistry, 1987, 48, 1486-1493.	3.9	43
78	Synaptosomal Sialyltransferase Glycosylates Surface Proteins that Are Inaccessible to the Action of Membraneâ€Bound Sialidase. Journal of Neurochemistry, 1986, 47, 1176-1180.	3.9	43
79	Characterization and Cellular Localization of a Developmentally Regulated Rat Neural Sialidase. Journal of Neurochemistry, 1986, 47, 18-22.	3.9	16